GeoVax Labs, Inc. develops vaccines and therapies for infectious diseases and cancers using a modified vaccinia ankara virus-like particle vaccine platform. They are working on vaccines for COVID-19, HIV, Zika, malaria, hemorrhagic fever viruses, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. They have partnerships with various institutions, including the National Institutes of Health and the Centers for Disease Control and Prevention.